Go to Samples
Jaypirca sample image

Eli Lilly and Co.

Jaypirca

100mg x 30 per package

Indications and Usage

Mantle Cell Lymphoma

JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

This indication is approved under accelerated approval based on response rate [see Clinical Studies ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

This indication is approved under accelerated approval based on response rate [see Clinical Studies ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

FAQs

All you need to know to order samples

Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.